繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-630

SNP-630

Indication
Non-alcoholic steatohepatitis (NASH)
Product Advantages
1. Optimized New Chemical Entity
2. First-in-class
3. For NASH and ASH
Status
1. Pre-clinical
2. SNP-630 and/or its active metabolites: some human experience
3. Plan to apply US FDA IND, fast track and breakthrough designation
Competitive Edge
1. Multiple mechanisms of action
2. Direct action on liver
3. Optimal potency
4. Great safety profile
Potential Market
The estimated global market for NASH: 35-40 B per year

Multiple Mechanisms of Action of SNP-6xx


模拟人生4 俱乐部赚钱 最新消息明天股票大 今日沪深股市行情查询 广东11选5一期一码计划 上海快3遗漏查询 福建36选7一注多少钱 安徽快三大小单双技巧 甘肃十一选五来开奖号 浙江11选5走势一定牛 配资炒股利息找中承配资 宁夏体彩十一选五周几开奖